An investigation on behalf of investors, who currently hold shares of OHR Pharmaceutical, Inc. (NASDAQ: OHRP), was announced concerning whether the takeover of OHR Pharmaceutical, Inc. is unfair to NASDAQ: OHRP stockholders.

The investigation by a law firm concerns whether certain officers and directors of OHR Pharmaceutical, Inc. breached their fiduciary duties owed to NASDAQ: OHRP investors in connection with the proposed acquisition.

New Yokr based OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. On Jan. 03, 2019 Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) announced that it has entered into a merger agreement with NeuBase Therapeutics, Inc, under which the stockholders of NeuBase would become the majority holders of the combined company.

However, the investigation concerns whether the offer is unfair to NASDAQ: OHRP stockholders. More specifically, the investigation concerns whether the OHR Pharmaceutical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On January 4, 2018, OHR Pharmaceutical, Inc. (NASDAQ: OHRP) shares closed at $0.16 per share.